methoxy polyethylene glycol-epoetin beta [Mircera]

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Anemia

Conditions

Anemia

Trial Timeline

Jul 1, 2008 → Oct 1, 2009

NCT ID

NCT00737711

About methoxy polyethylene glycol-epoetin beta [Mircera]

methoxy polyethylene glycol-epoetin beta [Mircera] is a approved stage product being developed by Roche for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00737711. Target conditions include Anemia.

What happened to similar drugs?

20 of 20 similar drugs in Anemia were approved

Approved (20) Terminated (5) Active (0)

✅Aranesp®AmgenApproved

✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved

✅Epoetin AlfaJohnson & JohnsonApproved

✅Roxadustat + rHuEPOAstraZenecaApproved

✅ICL670 + Chelation + No chelationNovartisApproved

✅cera, darbepoetin, epoetin-beta + ESARocheApproved

✅epoetin beta [NeoRecormon]RocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01342640	Approved	Completed	Jul 18, 2011	Nov 30, 2012	Anemia
NCT01156363	Approved	Completed	Oct 1, 2010	Jan 1, 2013	Anemia
NCT01191983	Approved	Completed	Aug 13, 2010	Apr 23, 2018	Anemia
NCT01066000	Approved	Terminated	Oct 31, 2009	Sep 30, 2011	Anemia
NCT00922116	Approved	Completed	Apr 30, 2009	Nov 30, 2010	Anemia
NCT00680563	Phase 3	Terminated	Apr 1, 2009	Jan 1, 2010	Anemia
NCT00882713	Phase 3	Completed	Feb 1, 2009	Oct 1, 2010	Anemia
NCT00922610	Approved	Completed	Feb 1, 2009	Jul 1, 2010	Anemia
NCT00737464	Approved	Completed	Aug 26, 2008	Sep 12, 2009	Anemia
NCT00661388	Phase 3	Completed	Aug 1, 2008	Dec 1, 2010	Anemia
NCT00737711	Approved	Completed	Jul 1, 2008	Oct 1, 2009	Anemia
NCT00576303	Phase 3	Completed	Apr 1, 2008	Jun 1, 2010	Anemia
NCT00642850	Phase 3	Completed	Nov 1, 2007	Jul 1, 2009	Anemia
NCT00517413	Phase 3	Completed	Oct 1, 2007	May 1, 2010	Anemia
NCT00413894	Phase 3	Completed	Mar 1, 2007	Oct 1, 2008	Anemia
NCT00048048	Phase 2	Completed	Mar 1, 2002	Nov 1, 2004	Anemia
NCT00048035	Phase 2	Completed	Mar 1, 2002	Jun 1, 2005	Anemia
NCT00364832	Phase 2	Completed	Oct 1, 2001	Jul 1, 2005	Anemia

Competing Products

20 competing products in Anemia

See all competitors

Product	Company	Stage	Hype Score
Aranesp®	Amgen	Approved	43
KER-047	Keros Therapeutics	Phase 2	17
LY2787106	Eli Lilly	Phase 1	29
R744 + R744	Chugai Pharmaceutical	Phase 3	40
epoetin beta + placebo	Chugai Pharmaceutical	Phase 3	40
recombinant human erythropoietin + recombinant human erythropoietin placebo	Chugai Pharmaceutical	Phase 3	40
recombinant human erythropoietin + recombinant human erythropoietin	Chugai Pharmaceutical	Phase 3	40
darbepoetin alfa	Amgen	Phase 3	40
Prasugrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Placebo	Daiichi Sankyo	Phase 2	35
roxadustat	Astellas Pharma	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
Roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	40
Alefacept	Astellas Pharma	Phase 1	21
Roxadustat	Astellas Pharma	Phase 2	35
roxadustat	Astellas Pharma	Phase 1	29
Roxadustat + Placebo	Astellas Pharma	Phase 3	40
Roxadustat	Astellas Pharma	Pre-clinical	26
Roxadustat + Epoetin Alfa	Astellas Pharma	Phase 3	40
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	40